Let's Continue to Raise Money for Breast Cancer!

Avon Products, Inc. is a US cosmetics, perfume and toy seller with markets in over 140 countries across the world and sales of $9.9 billion worldwide as of 2007.

Avon Products is a multi-level marketing companyhttp://www.bloomberg.com/apps/news?pid=newsarchive&sid=a8N_74GdteOg. Traditionally a direct marketing company, Avon's fastest growing markets today are in China and Russia. The company's chairman and CEO is Andrea Jung, who was promoted to the position in 1999. Avon's product lines include makeup, bath and skin lotions, anti-aging cream, perfumes, as well as jewelry and clothing.

Avon uses both door-to-door sales people ("Avon ladies," primarily and a growing number of men) and catalogs to advertise its products. In some markets, Avon products are sold primarily in retail stores (most notably China, which had banned all door-to-door selling before mid-December 2006).

Although the company has always been more directed toward female customers, Avon's line of male products continues to expand, and its children's products (such as shampoos and toys) have also proved successful.

In 2007, Reese Witherspoon signed a multiyear agreement to serve as Avon's global ambassador. The actress will be involved in product development, appear in advertisements, and will serve as the honorary chairman of the Avon Foundation.

Breast cancer refers to cancers originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas. There are many different types of breast cancer, with different stages (spread), aggressiveness, and genetic makeup; survival varies greatly depending on those factors. With best treatment, 10-year disease-free survival varies from 98% to 10%. Treatment includes surgery, drugs (hormonal therapy and chemotherapy), and radiation.

Worldwide, breast cancer comprises 10.4% of all cancer incidence among women, making it the second most common type of non-skin cancer (after lung cancer) and the fifth most common cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths). Breast cancer is about 100 times more common in women than in men, but survival rates are equal in both sexes.

Some breast cancers require the hormones estrogen and progesterone to grow, and have receptors for those hormones. After surgery those cancers are treated with drugs that interfere with those hormones, usually tamoxifen, and with drugs that shut off the production of estrogen in the ovaries or elsewhere; this may damage the ovaries and end fertility. Low-risk, hormone-sensitive breast cancers may be treated with hormone therapy and radiation alone. Breast cancers without hormone receptors, or which have spread to the lymph nodes in the armpits, or which express certain genetic characteristics, are higher-risk, and are treated more aggressively. One standard regimen, popular in the U.S., is cyclophosphamide plus doxorubicin (Adriamycin), known as CA; these drugs damage DNA in the cancer, but also in fast-growing normal cells where they cause serious side effects. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as CAT; taxane attacks the microtubules in cancer cells. An equivalent treatment, popular in Europe, is cyclophosphamide, methotrexate, and fluorouracil (CMF).Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055-65. Monoclonal antibodies, such as trastuzumab, are used for cancer cells that have the HER2 mutation. Radiation is usually added to the surgical bed to control cancer cells that were missed by the surgery, which usually extends survival, although radiation exposure to the heart may cause damage and heart failure in the following years.Buchholz TA. N Engl J Med. 2009 Jan 1;360(1):63-70. Radiation therapy for early-stage breast cancer after breast-conserving surgery.